Beleaguered Arrowhead 'Cautiously Optimistic' About RNAi Deal, Closes Calando's Lab

Meanwhile, in a filing with the US Securities and Exchange Commission, Arrowhead warned that its fiscal 2009 operating losses and negative cash flows from operations "raises doubts about its ability to continue as a going concern over the next 12 months and beyond."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.